DHHS Guidelines Add Tenofovir/FTC/Elvitegravir/Cobicistat as an Alternative Regimen for First-Line HIV Treatment

Tenofovir/FTC/elvitegravir/cobicistat is the first single-tablet antiretroviral regimen that includes an HIV integrase inhibitor rather than targeting reverse transcriptase alone.

The U.S. Department of Health and Human Services (DHHS) now recommends the single-tablet regimen tenofovir/FTC/elvitegravir/cobicistat (Stribild) as an alternative treatment for antiretroviral-naive HIV-infected patients with estimated creatinine clearance >70 mL/minute/1.73 m². The new tablet was recently approved by the FDA for use in antiretroviral-naive HIV-infected patients based on the results of two randomized trials. In both of those trials, the combination tablet was noninferior to a DHHS-preferred treatment regimen (tenofovir/FTC/efavirenz [Atripla] or tenofovir/FTC + ritonavir-boosted atazanavir) and was generally well tolerated (JW AIDS Clin Care Jul 9 2012).

The new single-tablet regimen is the first “one pill, once daily” table…

Reviewing Author

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

DHHS Guidelines Add Tenofovir/FTC/Elvitegravir/Cobicistat as an Alternative Regimen for First-Line HIV Treatment

Topics

Reviewing Author